RNA-based therapeutics are transforming medicine, but scaling production efficiently remains a challenge, particularly the ...

There's a new frontier in treating autoimmune diseases. Today's treatments tamp down the friendly fire but don't fix what's ...

Mursla Bio, a leader in Extracellular Vesicle (EV) science on a mission to advance precision diagnostics and significantly improve chronic disease outcomes for at-risk patients, today announced a ...

A presentation by scientists on a work group for the Centers for Disease Control and Prevention’s vaccine advisory panel ...

Mursla Bio has announced a new collaboration with a leading global pharmaceutical company to support biomarker-guided drug ...

The 9 therapeutics stocks we track reported a mixed Q3. As a group, revenues beat analysts’ consensus estimates by 5.7%. In ...

Studies including a randomized clinical trial from 1976 found monitoring did not reduce the number of deaths among newborns, ...

New Volume Expands Global Reach of Independent Science as Public Demand Grows for Transparency in Health Research WASHINGTON, Nov. 12, 2025 /PRNewswire/ -- The Independent Medical Alliance (IMA) today ...

AML is a devastating blood cancer with low survival rates, particularly for older patients who cannot tolerate aggressive chemotherapy. Flashpoint's approach offers the potential for a new precision ...

Four new patent applications filed that aim to expand the Curadigm Nanoprimer platform intellectual property portfolio and support an initial ...